Allakos Inc. is a biopharmaceutical company that develops new therapeutics for immunomodulatory receptors present in various diseases. Their lead monoclonal antibody is lirentelimab, which is currently being studied in Phase III and Phase II/III clinical trials for various diseases such as eosinophilic gastritis and eosinophilic esophagitis. The company is also developing lirentelimab for the treatment of other diseases like mast cell gastrointestinal disease, chronic urticaria, and severe allergic conjunctivitis.